References
1. Global, regional, and national incidence, prevalence, and years lived
with disability for 328 diseases and injuries for 195 countries,
1990-2016: a systematic analysis for the Global Burden of Disease Study
2016. Lancet. 2017;390(10100):1211-59.
2. Gauthier M, Ray A, Wenzel SE. Evolving Concepts of Asthma. Am J
Respir Crit Care Med. 2015;192(6):660-8.
3. Kuruvilla ME, Lee FE, Lee GB. Understanding Asthma Phenotypes,
Endotypes, and Mechanisms of Disease. Clin Rev Allergy Immunol.
2019;56(2):219-33.
4. Barnes PJ. Glucocorticosteroids. Handb Exp Pharmacol.
2017;237:93-115.
5. Global Initiative for Asthma. Global Strategy for Asthma Management
and Prevention, 2020. Available from: www.ginasthma.org.
6. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al.
International ERS/ATS guidelines on definition, evaluation and treatment
of severe asthma. Eur Respir J. 2014;43(2):343-73.
7. Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term Systemic
Corticosteroid Exposure: A Systematic Literature Review. Clin Ther.
2017;39(11):2216-29.
8. Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, et al.
Short term use of oral corticosteroids and related harms among adults in
the United States: population based cohort study. BMJ. 2017;357:j1415.
9. Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, et al.
Adverse outcomes from initiation of systemic corticosteroids for asthma:
long-term observational study. J Asthma Allergy. 2018;11:193-204.
10. Bleecker ER, Menzies-Gow AN, Price DB, Bourdin A, Sweet S, Martin
AL, et al. Systematic Literature Review of Systemic Corticosteroid Use
for Asthma Management. Am J Respir Crit Care Med. 2020;201(3):276-93.
11. Sullivan PW, Ghushchyan VH, Globe G, Schatz M. Oral corticosteroid
exposure and adverse effects in asthmatic patients. J Allergy Clin
Immunol. 2018;141(1):110-6 e7.
12. Ramsahai JM, Wark PA. Appropriate use of oral corticosteroids for
severe asthma. Med J Aust. 2018;209(S2):S18-S21.
13. Bourdin A, Adcock I, Berger P, Bonniaud P, Chanson P, Chenivesse C,
et al. How can we minimise the use of regular oral corticosteroids in
asthma? Eur Respir Rev. 2020;29(155).
14. Price D, Castro M, Bourdin A, Fucile S, Altman P. Short-course
systemic corticosteroids in asthma: striking the balance between
efficacy and safety. Eur Respir Rev. 2020;29(155).
15. Tan R, Liew MF, Lim HF, Leung BP, Wong WSF. Promises and challenges
of biologics for severe asthma. Biochem Pharmacol. 2020;179:114012.
16. Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas
J, Schmidt M. Data Resource Profile: The Danish National Prescription
Registry. Int J Epidemiol. 2017;46(3):798-f.
17. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L,
Sorensen HT. The Danish National Patient Registry: a review of content,
data quality, and research potential. Clin Epidemiol. 2015;7:449-90.
18. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration
System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541-9.
19. Pont LG, van der Werf GT, Denig P, Haaijer-Ruskamp FM. Identifying
general practice patients diagnosed with asthma and their exacerbation
episodes from prescribing data. Eur J Clin Pharmacol.
2002;57(11):819-25.
20. Ortqvist AK, Lundholm C, Wettermark B, Ludvigsson JF, Ye W, Almqvist
C. Validation of asthma and eczema in population-based Swedish drug and
patient registers. Pharmacoepidemiol Drug Saf. 2013;22(8):850-60.
21. Ekstrom M, Nwaru BI, Hasvold P, Wiklund F, Telg G, Janson C. Oral
corticosteroid use, morbidity and mortality in asthma: A nationwide
prospective cohort study in Sweden. Allergy. 2019;74(11):2181-90.
22. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al.
Updating and validating the Charlson comorbidity index and score for
risk adjustment in hospital discharge abstracts using data from 6
countries. Am J Epidemiol. 2011;173(6):676-82.
23. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT.
The predictive value of ICD-10 diagnostic coding used to assess Charlson
comorbidity index conditions in the population-based Danish National
Registry of Patients. BMC Med Res Methodol. 2011;11:83.
24. Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J.
2009;33(4):897-906.
25. Davydow DS, Ribe AR, Pedersen HS, Fenger-Gron M, Cerimele JM,
Vedsted P, et al. Serious Mental Illness and Risk for Hospitalizations
and Rehospitalizations for Ambulatory Care-sensitive Conditions in
Denmark: A Nationwide Population-based Cohort Study. Med Care.
2016;54(1):90-7.
26. Pedersen MS, Benros ME, Agerbo E, Borglum AD, Mortensen PB.
Schizophrenia in patients with atopic disorders with particular emphasis
on asthma: a Danish population-based study. Schizophr Res.
2012;138(1):58-62.
27. Hallas J, Stovring H. Templates for analysis of individual-level
prescription data. Basic Clin Pharmacol Toxicol. 2006;98(3):260-5.
28. Tran TN, King E, Sarkar R, Nan C, Rubino A, O’Leary C, et al. Oral
corticosteroid prescription patterns for asthma in France, Germany,
Italy and the UK. Eur Respir J. 2020;55(6).
29. Belhassen M, Nolin M, Nibber A, Ginoux M, Devouassoux G, Van Ganse
E. Changes in Persistent Asthma Care and Outcomes From 2006 to 2016 in
France. J Allergy Clin Immunol Pract. 2019;7(6):1858-67.
30. Bloom CI, Walker S, Quint JK. Inadequate specialist care referrals
for high-risk asthma patients in the UK: an adult population-based
cohort 2006-2017. J Asthma. 2021;58(1):19-25.
31. Davidsen JR, Sondergaard J, Hallas J, Siersted HC, Lykkegaard J,
Andersen M. Increased use of inhaled corticosteroids among young Danish
adult asthmatics: an observational study. Respir Med.
2010;104(12):1817-24.
32. Schmidt M, Schmidt SAJ, Adelborg K, Sundboll J, Laugesen K,
Ehrenstein V, et al. The Danish health care system and epidemiological
research: from health care contacts to database records. Clin Epidemiol.
2019;11:563-91.